Immunicum's abstract with data from a kidney cancer study has been approved for presentation at the 2014 ASCO Annual Meeting in Chicago
Göteborg, Sweden, 2014-03-27 10:25 CET (GLOBE NEWSWIRE) -- Immunicum today announced that an abstract has been approved to for presentation at the American Society of Clinical Oncology's's, ASCO, annual convention held in Chicago May 30-June 3, 2014.
The abstract, with title "Intratumoral vaccination with activated allogeneic dendritic cells in patients with newly diagnosed metastatic renal cell carcinoma (mRCC)", presents clinical data from the newly finalized phase I/II-study on kidney cancer patients treated with INTUVAX®.
- Being accepted to present at the most prestigious cancer conference in the world creates a great opportunity for us to showcase Immunicum's technology and shows the level of scientific interest our clinical data has generated, says Immunicum's CEO, Jamal El-Mosleh.
Immunicum recently received the results of the data for the phase I/II In trial in patients with metastatic renal cell carcinoma (mRCC)"
"We are pleased to report conclusions that can be crucial for the survival time in patients with mRCC" says Jamal El-Mosleh, the CEO of Immunicum.
During the ASCO annual meeting more data is to be presented to the meeting participants and the media.
Immunicum's immunotherapy plattforms are based on over 30 years of research in the field of transplantation immunology. The Company's shares have been traded since April 22, 2013 on NASDAQ OMX First North under the ticker IMMU.
For further information please contact:
Jamal El-Mosleh, CEO of Immunicum, +4631-41 50 53,
Redeye AB is chosen as the Company's Certified Adviser.
Tel: +468-545 013 31. www.redeye.se.
About Immunicum AB (publ):
Immunicum AB (publ) develops cancer immunotherapies. Its two main groups of therapeutic cancer vaccines, SUBCUVAX® and INTUVAX®, and the method of expansion of tumor-specific T-cells (CD70) is based on the Nobel prize awarded discovery of the dendritic cell and its central role in the activation of the specific immune response. Since the raw material consists of allogeneic dendritic cells, Immunicum's products can be produced in large scale. The vaccines are now undergoing clinical trials in renal cell carcinoma and hepatocellular carcinoma.